These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 1687299)

  • 1. [Correlation between pharmacokinetics and dynamics: explanation of clinical aspects exemplified by beta-receptor blockers].
    Palm D; Wellstein A; Schloos J; Belz GG
    Verh Dtsch Ges Inn Med; 1991; 97():338-42. PubMed ID: 1687299
    [No Abstract]   [Full Text] [Related]  

  • 2. [Activity profile of beta blockers].
    Drexel H
    Praxis (Bern 1994); 1995 Mar; 84(10):278-80. PubMed ID: 7892547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Alternating dosage of bisoprolol?].
    Wehling M
    Internist (Berl); 1998 Mar; 39(3):316. PubMed ID: 9561455
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics of atenolol in clinically normal cats.
    Quiñones M; Dyer DC; Ware WA; Mehvar R
    Am J Vet Res; 1996 Jul; 57(7):1050-3. PubMed ID: 8807020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical pharmacology of beta-adrenergic blockers.
    Lowenthal DT
    Cardiovasc Clin; 1984; 14(3):61-71. PubMed ID: 6144391
    [No Abstract]   [Full Text] [Related]  

  • 6. A pharmacokinetic comparison of generic tablets containing bisoprolol with the innovator formulation in healthy volunteers.
    Jovanović D; Cusić S; Rancić D; Srnić D; Perković-Vukcević N
    J Clin Pharmacol; 2006 Oct; 46(10):1217-22. PubMed ID: 16988212
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmacology and clinical pharmacokinetics of nadolol].
    Lazowski J; Wegrzyn B; Lypka A
    Pol Tyg Lek; 1981 Sep; 36(39):1521-4. PubMed ID: 6121320
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics of beta-adrenoceptor blocking agents: clinical significance of hepatic and/or renal clearance.
    Borchard U
    Clin Physiol Biochem; 1990; 8 Suppl 2():28-34. PubMed ID: 1982759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacokinetic and biological effective time of beta-receptor blockers in renal insufficiency].
    Knauf H; Schäfer-Korting M; Mutschler E
    Internist (Berl); 1981 Oct; 22(10):616-21. PubMed ID: 6117538
    [No Abstract]   [Full Text] [Related]  

  • 10. [Elimination of drugs. Elimination half-life of a drug].
    Della Negra M; Woronoff-Lemsi MC
    Soins; 1998; (627):57-8. PubMed ID: 9783022
    [No Abstract]   [Full Text] [Related]  

  • 11. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans.
    Mehvar R; Brocks DR
    J Pharm Pharm Sci; 2001; 4(2):185-200. PubMed ID: 11466176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Importance and limitations of metabolic drug half-life].
    Buclin T; Biollaz J
    Praxis (Bern 1994); 1997 Oct; 86(43):1693-7. PubMed ID: 9432694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor binding characteristics and pharmacokinetic properties as a tool for the prediction of clinical effects of beta-blockers.
    Wellstein A; Palm D; Belz GG; Pitschner HF
    Arzneimittelforschung; 1985; 35(1):2-6. PubMed ID: 2859024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetics and -dynamics of calcium antagonists in the elderly].
    Spahn-Langguth H; Möhrke W; Mutschler E; Platt D
    Fortschr Med; 1993 Oct; 111(28):441-5. PubMed ID: 8282288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy.
    Magnusson Y; Levin MC; Eggertsen R; Nyström E; Mobini R; Schaufelberger M; Andersson B
    Clin Pharmacol Ther; 2005 Sep; 78(3):221-31. PubMed ID: 16153393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biliary elimination of the selective beta-receptor blocking drug talinolol in man.
    Terhaag B; Gramatté T; Richter K; Voss J; Feller K
    Int J Clin Pharmacol Ther Toxicol; 1989 Apr; 27(4):170-2. PubMed ID: 2565889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response.
    Sowinski KM; Burlew BS
    Pharmacotherapy; 1997; 17(6):1305-10. PubMed ID: 9399616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic models of various beta blockers: an explanation for the long duration of action of bopindolol.
    Grevel J
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S16-9. PubMed ID: 2439812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.
    Luzier AB; Killian A; Wilton JH; Wilson MF; Forrest A; Kazierad DJ
    Clin Pharmacol Ther; 1999 Dec; 66(6):594-601. PubMed ID: 10613615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.